Xycrobe’s technology platform addresses the need of patients with inflammatory skin disease through the development of a library of good bacteria strains designed to be used for therapeutic purposes. With our technology, we aim to change the way inflammatory skin disease is treated by 1) addressing bacterial dysbiosis of the skin, 2) addressing immunological or genetic deficiencies found in many affected patients and 3) reducing the incidence of antibiotic-resistant b
LifeSci
Xycrobe Therapeutics
OTHER COMPANIES
